ESR1 and breast cancer: These hybrids combine two key pharmacophores—indole and sulfonylhydrazone—and were subjected to in silico screening to evaluate drug likeness, pharmacokinetic properties, and in vitro anticancer activity against two breast cancer cell lines: MCF-7 (ER-α+) and MDA-MB-231 (triple-negative).